IMR Press / EJGO / Volume 38 / Issue 6 / DOI: 10.12892/ejgo3724.2017

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Adjuvant docetaxel and carboplatin chemotherapy for patients with high-intermediate and high-risk endometrial cancer
Show Less
1 Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
Eur. J. Gynaecol. Oncol. 2017, 38(6), 917–920; https://doi.org/10.12892/ejgo3724.2017
Published: 10 December 2017
Abstract

Purpose: A phase II study was conducted to confirm the efficacy and toxicity of docetaxel and carboplatin in patients with high-intermediate and high-risk endometrial cancer in an adjuvant setting. Materials and Methods: Eligible women had histologically verified endometrioid adenocarcinoma and Stage IC/IIG3 with deep myometrial invasion or Stage III disease. Docetaxel 70 mg/m2 and carboplatin AUC 5 were administered every three weeks for six cycles. The primary end point was to evaluate the five-year PFS rate and the secondary end point was to assess adverse events. Results: The five-year OS rate was 90.8% while the five-year DFS rate was 85.4%. Because of the hypersensitivity reactions, chemotherapy regimen was changed in two patients, and the protocol therapy was discontinued in two patients by patient’s will after two cycles and four cycles, respectively. Conclusion: Docetaxel and carboplatin combination chemotherapy may be one of the applicable adjuvant treatments for this group of patients.
Keywords
High-intermediate/high-risk endometrial cancer
Adjuvant chemotherapy
Docetaxel/carboplatin
Phase II study
Share
Back to top